Disease · MONDO_0017844

Sezary syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Sezary syndrome. Diseases, record MONDO_0017844. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0017844

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Sezary syndrome; Open Targets
Open Targets ID: MONDO_0017844; Open Targets
Other names: CTCL / Sezary syndrome, SC)zary syndrome, Sezary disease, Sezary lymphoma, Sezary's disease, Sézary lymphoma, Sézary syndrome, cutaneous T-cell lymphoma/Sezary syndrome; Open Targets
Disease Ontology: DOID:8541; Disease Ontology
MeSH: D012751; MeSH
NCI Thesaurus: C3366; NCI Thesaurus
Orphanet: ORPHA:3162; Orphanet
Highest stage of its drugs: Approval, for 1 of its 50 drugs, from EMA Human Drugs, FDA and TTD; Open Targets

Drugs50

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MOGAMULIZUMAB	CHEMBL1743041	Antibody	Approval	EMA Human Drugs, FDA and TTD	12	9	9	Drugs and targets
RESMINOSTAT	CHEMBL4296717	Small molecule	Preapproval	EMA Human Drugs	1	0	0	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
VORINOSTAT	CHEMBL98	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
NALOXONE HYDROCHLORIDE	CHEMBL1718	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ZANOLIMUMAB	CHEMBL2108063	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BRENTUXIMAB VEDOTIN	CHEMBL1742994	Antibody drug conjugate	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
ALEMTUZUMAB	CHEMBL1201587	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 50

See all 50 drugs

Targets85

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HDAC1	Histone deacetylase	3	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Phase 3	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	3	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Phase 3	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	3	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Phase 3	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Histone deacetylase	3	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Phase 3	https://conductscience.org/library/genes/10013	Drugs and targets
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
DHFR	Dihydrofolate reductase	2	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
HDAC10	Histone deacetylase	2	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/83933	Drugs and targets
HDAC11	Histone deacetylase	2	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/79885	Drugs and targets
HDAC4	Histone deacetylase	2	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/9759	Drugs and targets
HDAC5	Histone deacetylase	2	Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/10014	Drugs and targets

1 to 10 of 85

See all 85 targets

Trials51

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01728805	Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL	Phase 3	372	2019-04-11	Cutaneous T-Cell Lymphoma	MOGAMULIZUMAB, VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT02663518	A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors	Phase 1	249	2024-05-10	Hematologic Malignancies, Solid Tumor	NIVOLUMAB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00425555	Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma	Phase 2	139	2021-08-16	Cutaneous T-Cell Lymphoma	PANOBINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT03493451	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Phase 2	77	2022-05-04	Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK T Cell Lymphoma, Extranodal NK T Cell Lymphoma, Nasal, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory, Peripheral T-cell Lymphoma NOS, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Peripheral T-Cell Lymphoma Refractory, Anaplastic Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, ALK-negative Anaplastic Large Cell Lymphoma, ALK-Positive Anaplastic Large Cell Lymphoma, Cutaneous T-cell Lymphoma	TISLELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00896493	Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma	Phase 2	38	2023-05-11	Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Cutaneous T-cell Lymphoma	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT01396070	Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level	Phase 2	36	2017-04-05	Non-Hodgkin Lymphoma (NHL), Cutaneous Lymphoma, Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome	BRENTUXIMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov
NCT00466921	Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome	Phase 2	33	2020-11-16	Lymphoma	LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT03063632	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma	Phase 2	28	2022-08-30	Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma	INTERFERON GAMMA-1B, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00907738	A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)	Phase 2	27	2011-07-14	Advanced Cancer	VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00744991	A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma	Phase 2	25	2020-10-19	Cutaneous T-Cell Lymphoma	ENZASTAURIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 51

See all 51 trials

Comparisons in its trials11

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Bexarotene Exposed vs Bexarotene Naive: deaths from any cause	3 of 79	3 of 60	139	NCT00425555	Trial comparisons
Bexarotene Exposed vs Bexarotene Naive: serious adverse events	33 of 79	23 of 60	139	NCT00425555	Trial comparisons
Parts 2 and 3 : Cutaneous T-cell Lymphoma (CTCL) vs Parts 2 and 3: T-cell Lymphoma (TCL): Parts 2 and 3: Overall Response Rate (ORR)-Olsen 2011-Disease Indication	2 of 21	5 of 29	50	NCT02663518	Trial comparisons
Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): Overall Response Rate (ORR)	6 of 16	0 of 12	28	NCT03063632	Trial comparisons
Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): Incidence of Adverse Events	15 of 16	12 of 12	28	NCT03063632	Trial comparisons
Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): deaths from any cause	4 of 16	6 of 12	28	NCT03063632	Trial comparisons
Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): serious adverse events	4 of 16	5 of 12	28	NCT03063632	Trial comparisons
Part 2: Myelodysplastic Syndrome (MDS) vs Part 2: Myeloproliferative Neoplasms (MPN): Part 2: Overall Response Rate (ORR)-Savona 2015- Disease Indication	0 of 6	1 of 3	9	NCT02663518	Trial comparisons
Dose Level 1 (Interleukin-15 2mcg/kg/Day) vs Dose Level 2 (Interleukin-15 4mcg/kg/Day): Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	3 of 3	3 of 3	6	NCT04185220	Trial comparisons
Dose Level 1 (Interleukin-15 2mcg/kg/Day) vs Dose Level 2 (Interleukin-15 4mcg/kg/Day): deaths from any cause	2 of 3	1 of 3	6	NCT04185220	Trial comparisons

1 to 10 of 11

See all 11 comparisons in its trials

Papers from its trials22

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32941647	RESULT	1	PubMed
22981498	RESULT	1	PubMed
19951879	RESULT	1	PubMed
12543862	RESULT	1	PubMed
40601335	DERIVED	1	PubMed
40546724	DERIVED	1	PubMed
39315857	DERIVED	1	PubMed
37276067	DERIVED	1	PubMed
36841672	DERIVED	1	PubMed
34795254	DERIVED	1	PubMed

1 to 10 of 22

See all 22 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0017844

GET https://conductscience.org/api/diseases/v1/MONDO_0017844/drugs?page=2

API reference For AI assistants